8-K Announcements
6Material company update
May 18, 2026·SEC
Material company update
Nov 12, 2025·SEC
Material company update
Nov 6, 2025·SEC
Palatin Technologies, Inc.(PTN)Earnings, Financials & Key Ratios
PTN•AMEX
$11.01
Price updated Jul 6, 2026
AboutPalatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.Show more
- Revenue$0-100.0%
- EBITDA-$17M+22.4%
- Net Income-$17M+41.8%
- EPS (Diluted)-32.15-1491.6%
PTN Price & Volume
Palatin Technologies, Inc. (PTN) stock price & volume — 10-year historical chart
Loading chart...
Erratic Milestone Revenue Masks Structural Liquidity Risks
Investment Thesis • Updated 2026Q3
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
Key Thesis Takeaways
- Palatin Technologies remains fundamentally constrained by a business model reliant on lumpy, non-recurring milestone payments rather than sustainable commercial sales of Vyleesi.
- The company's persistent inability to achieve positive operating leverage, evidenced by R&D expenditures that frequently dwarf quarterly revenue, suggests a high risk of continued shareholder dilution.
- Investors should monitor the precarious $10.2 million cash position against historical quarterly burn rates, as the lack of tangible, income-generating assets leaves little margin for operational error.
Verdict Logic
the company's reliance on non-recurring revenue and a $10.2 million cash balance against significant historical burn rates suggests an imminent risk of dilutive financing to maintain operations.
PTN Growth Metrics
Palatin Technologies, Inc. (PTN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM3581.22%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM73.21%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-63.78%
Return on Capital
10 Years-273.76%
5 Years-396.73%
3 Years-721.49%
Last Year-
PTN Recent Earnings
Palatin Technologies, Inc. (PTN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (64%)●Beat Revenue 2/12 qtrs (40%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.37+70.2%
$1.24
Rev
$50,000-96.1%
$1M
Q1 2026
Feb 17, 2026Metric
Actual
Est
EPS
$2.86-21.5%
$2.35
Rev
$116,036+364.1%
$25,000
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$4.26
—
Rev
$9M
—
Q4 2025
Sep 23, 2025Metric
Actual
Est
EPS
$4.14+56.4%
$9.50
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.37vs $1.24+70.2% | $50,000vs $1M-96.1% |
| Q1 2026 | Feb 17, 2026 | $2.86vs $2.35-21.5% | $116,036vs $25,000+364.1% |
| Q4 2025 | Nov 14, 2025 | $4.26 | $9M |
| Q4 2025 | Sep 23, 2025 | $4.14vs $9.50+56.4% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Palatin Technologies, Inc. (PTN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $11.01 | $12.09M | -0.34 | -100% | — | — | — | |
| $2.08 | $30.21M | -1.73 | 10429.36% | -1038.77% | — | — | |
| $3.38 | $21.35M | -2.79 | 125.12% | -102.42% | -61.46% | — | |
| $11.09 | $1.53B | -1.08 | -2.75% | -43.5% | -50.65% | — | |
| $85.05 | $1.93B | 25.62 | 43.78% | 9.71% | 17.32% | — | |
| $38.28 | $8.4B | 75.06 | 59% | -0.56% | -2.48% | — |
Compare PTN vs Peers
Palatin Technologies, Inc. (PTN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PTN SEC Filings & Documents
Palatin Technologies, Inc. (PTN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PTN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PTN Frequently Asked Questions
Palatin Technologies, Inc. (PTN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Palatin Technologies, Inc.'s revenue?
Palatin Technologies, Inc. (PTN) reported $12.9M in revenue for fiscal year 2025. This represents a 64321% increase from $0.0M in 1996.
How fast is Palatin Technologies, Inc. growing?
Palatin Technologies, Inc. (PTN) saw revenue decline by 100.0% over the past year.
Is PTN profitable?
Palatin Technologies, Inc. (PTN) reported a net loss of $6.2M for fiscal year 2025.
Dividend & Returns
What is Palatin Technologies, Inc.'s free cash flow?
Palatin Technologies, Inc. (PTN) had negative free cash flow of $15.0M in fiscal year 2025, likely due to heavy capital investments.